Novel strains of Lactobacillus plantarum GCWB1001 deposited as accession number KCCM12698P, Pediococcus acidilactici GCWB1085 deposited as accession number KCCM12699P, or Lactobacillus rhamnosus GCWB1156 deposited as accession number KCCM12700P are disclosed. The novel strains have the excellent effect of treating or alleviating respiratory diseases. Additionally, provided are a pharmaceutical composition, a health functional food composition, and probiotics, all of which have the effect of treating or alleviating inflammatory diseases or respiratory diseases, containing any one of the novel strains.

Provided is a composition for preventing and treating lipid-related metabolic diseases, the composition comprising, as an active ingredient, Lactobacillus plantarum ATG-K2 or Lactobacillus plantarum ATG-K6 isolated from fermented vegetables.

The present invention relates to a Lactobacillus plantarum capsule and use thereof, and belongs to the technical field of microbe feed additives. The Lactobacillus plantarum capsule consists of a wall material, Lactobacillus plantarum, a cryoprotectant, stachyose, and Morchella esculenta zymolytic powders; wherein the wall material is composed of zymolytic soybean protein isolate, chitosan, xanthan gum, carrageenin, glycerin and trehalose, and when formulated into a mixed solution, the above substances have concentrations of 7 to 10% zymolytic soybean protein isolate, 1 to 2% chitosan, 1 to 3% xanthan gum, 0.1 to 0.5% carrageenin, 0.3 to 1% glycerin, and 0.5 to 2% trehalose. The Lactobacillus plantarum capsule of the present invention enhances resistance of the capsule to gastric acid, has very good enteric solubility, besides, it can effectively inhibit the growth of pathogenic germs to improve immunity, decrease incidence of diseases in livestock and poultry, and improve the breeding quality and benefit.

The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.

The present invention relates to a method for manufacturing a proteo-oleaginous-based fermented food product and to the product obtained by means of this method. The product is characterized by an origin that may be 100% plant-based, and in particular free of dairy or animal product and therefore perfectly suitable for individuals on a lactose-free or vegan diet. The method comprises steps of grinding and/or homogenizing, of mixing with ferments, of incubating, and optionally of salting.

The present disclosure relates to a method for preparing an aglycone or hydrolyzed glycoside converted from a glycoside and, specifically, to a method for preparing an aglycone or hydrolyzed glycoside from a glycoside by converting a glycoside into an aglycone form or hydrolyzed glycoside by using a microorganism producing β-glycosidase, and then recovering the aglycone or hydrolyzed glycoside accumulated in the cells of the microorganism.

This disclosure relates generally to a microbial treatment for poultry. More particularly, the disclosure relates to a direct fed microbial composition including one or more lactic acid bacteria strains in combination with one or more Bacillus bacteria strains configured to inhibit gastrointestinal pathogens in a bird. A method of use is also disclosed herein.

The invention relates to a pharmaceutical and/or dietetic composition for increasing the impact of the immune defense of higher living beings, wherein bacteria of the species Lactobacillus fermentum from at least one of the strains K1-Lb1 or K1-Lb6 or K2-Lb4 or K6-Lb4 or K7-Lb1 or K8-Lb1 or K9-Lb6 are contained in order to control the adaptive and natural immune defense by means of T helper 1 and T helper 2 cells and/or bacteria of the species Lactobacillus fermentum from at least one of the strains K2-Lb6 or K11-Lb3 are contained in order to strengthen the native immune defense.

Disclosed is a novel lactic acid bacterium belonging to Lactobacillus plantarum, which has an excellent fermentative ability affording high achievable cell counts even if various vegetable or fruit juices are used as fermentative substrates. The lactic acid bacterium belonging to Lactobacillus plantarum is characterized by the achievable viable cell counts being 10.sup.8 CFU/ml or more in both cases when 100% juice of grape or of orange is used as fermentative substrate.

Isolates strains of gastrointestinal bacteria from wolves are provided for use as probiotics. In some embodiments, the isolated strains are for use as probiotics in canine subjects such as domestic dogs. In some embodiments, the isolated strains may be used to treat or prevent intestinal dysbiosis in the subject. Also provided are compositions comprising at least one isolated strain of wolf probiotic bacteria and related methods for making same.